- Home
- LCFY vs SYRS Comparison
LCFY vs SYRS Comparison
Compare LCFY & SYRS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- LCFY
- SYRS
- Stock Information
- Founded
- LCFY 2009
- SYRS 2011
- Country
- LCFY Australia
- SYRS United States
- Employees
- LCFY N/A
- SYRS N/A
- Industry
- LCFY
- SYRS Biotechnology: Pharmaceutical Preparations
- Sector
- LCFY
- SYRS Health Care
- Exchange
- LCFY Nasdaq
- SYRS Nasdaq
- Market Cap
- LCFY 7.3M
- SYRS 7.1M
- IPO Year
- LCFY 2022
- SYRS 2016
- Fundamental
- Price
- LCFY $7.60
- SYRS $0.21
- Analyst Decision
- LCFY
- SYRS Hold
- Analyst Count
- LCFY 0
- SYRS 5
- Target Price
- LCFY N/A
- SYRS $3.00
- AVG Volume (30 Days)
- LCFY 29.7K
- SYRS 3.5M
- Earning Date
- LCFY 11-12-2024
- SYRS 10-31-2024
- Dividend Yield
- LCFY N/A
- SYRS N/A
- EPS Growth
- LCFY N/A
- SYRS N/A
- EPS
- LCFY N/A
- SYRS N/A
- Revenue
- LCFY $2,668,385.00
- SYRS $386,000.00
- Revenue This Year
- LCFY N/A
- SYRS N/A
- Revenue Next Year
- LCFY N/A
- SYRS $1,011.11
- P/E Ratio
- LCFY N/A
- SYRS N/A
- Revenue Growth
- LCFY N/A
- SYRS N/A
- 52 Week Low
- LCFY $2.20
- SYRS $0.18
- 52 Week High
- LCFY $11.23
- SYRS $8.17
- Technical
- Relative Strength Index (RSI)
- LCFY 58.98
- SYRS 29.09
- Support Level
- LCFY $5.85
- SYRS $0.20
- Resistance Level
- LCFY $7.15
- SYRS $0.26
- Average True Range (ATR)
- LCFY 0.31
- SYRS 0.02
- MACD
- LCFY -0.01
- SYRS 0.07
- Stochastic Oscillator
- LCFY 76.36
- SYRS 11.39
About LCFY Locafy Limited
Locafy Ltd is focused on commercializing its Software as a Service (SaaS) online publishing technology platform. Its platform enables the ability to publish almost any type of content to almost any device that uses a web browser to display web content. The firm has three operating segments: the Publishing segment, the Reseller segment, and the Channel sales segment. It derives a majority of its revenue from Australia and New Zealand.
About SYRS Syros Pharmaceuticals Inc.
Syros Pharmaceuticals Inc is a biopharmaceutical company committed to developing new standards of care for the frontline treatment of patients with hematologic malignancies.